EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenic cell death unlocks the potential for combined radiation and immunotherapy

Somiya Rauf iD, Alexandra Smirnova, Andres Chang iD, Yuan Liu, Yi Jiang iD

Proceedings of the National Academy of Sciences · 02.12.2025 · 122 (48)

DOI: 10.1073/pnas.2509875122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 26.11.2025. Verfasst von Somiya Rauf und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Mathematics and Statistics, Georgia State University, Atlanta, GA 30303. Hauptthemen laut MEDLINE: Immunotherapy, Immunogenic Cell Death, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation (NSF), NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunogenic cell death (ICD) enhances antitumor immunity by releasing tumor-associated antigens and activating the antitumor immune system response. Here, we develop a mathematical model to quantify the role of ICD in optimizing the efficacy of combined radiotherapy (RT) and macrophage-based immunotherapy. Using preclinical murine data targeting the SIRP α -CD47 checkpoint, we show that RT alone induces minimal ICD, whereas disrupting the SIRP α -CD47 axis significantly enhances both phagocytosis and systemic immune activation. Our model predicts an optimal RT dose (6 to 8 Gy) for maximizing ICD, a dose-dependent abscopal effect, and a hierarchy of treatment efficacy, with SIRP α -knockout macrophages exhibiting the strongest tumoricidal activity. These findings provide a quantitative framework for designing more effective combination therapies, leveraging ICD to enhance immune checkpoint inhibition and radiotherapy synergy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyImmunogenic Cell DeathNeoplasmsAnimalsMiceCombined Modality TherapyHumansMacrophagesCD47 AntigenPhagocytosis

Stichwörter der Autor:innen

SIRPα-CD47 blockadeimmune checkpoint inhibitorimmunogenic cell deathphagocytosisradiotherapy

Substanzen

CD47 Antigen

Autor:innen und Institutionen

  • Department of Mathematics and Statistics, Georgia State University, Atlanta, GA 30303.
  • Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322.
  • Key State Laboratory of Pharmaceutical Biotechnology, Nanjing University School of Life Sciences, Nanjing, Jiangsu 210046, China.

ORCID-Profile: Somiya Rauf, Andres Chang, Yi Jiang

Förderung

  • National Science Foundation (NSF)
  • NIAID NIH HHS
  • NCI NIH HHS
  • HHS | NIH | National Cancer Institute (NCI)
  • HHS | NIH | National Center for Advancing Translational Sciences (NCATS)
  • NCATS NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Rauf, S., Smirnova, A., Chang, A., Liu, Y., & Jiang, Y. (2025). Immunogenic cell death unlocks the potential for combined radiation and immunotherapy. Proceedings of the National Academy of Sciences, 122(48). https://doi.org/10.1073/pnas.2509875122

Vancouver

Rauf S, Smirnova A, Chang A, Liu Y, Jiang Y. Immunogenic cell death unlocks the potential for combined radiation and immunotherapy. Proceedings of the National Academy of Sciences. 2025;122(48). doi:10.1073/pnas.2509875122

BibTeX
@article{Rauf2025,
  author = {Rauf, Somiya and Smirnova, Alexandra and Chang, Andres and Liu, Yuan and Jiang, Yi},
  title = {Immunogenic cell death unlocks the potential for combined radiation and immunotherapy},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {48},
  doi = {10.1073/pnas.2509875122}
}
Kostenlos starten →